DOSE OPTIMIZATION STUDY OF ARTERIAL CHANGES ASSOCIATED WITH ANGIOTENSIN CONVERTING ENZYME-INHIBITION IN HYPERTENSION

被引:8
作者
ASMAR, RG
IANNASCOLI, F
BENETOS, A
SAFAR, ME
机构
[1] HOP BROUSSAIS,DEPT INTERNAL MED,SERV MED 1,96 RUE DIDOT,F-75674 PARIS 14,FRANCE
[2] HOP BROUSSAIS,INSERM,U337,F-75674 PARIS 14,FRANCE
关键词
HYPERTENSION; ANGIOTENSIN CONVERTING ENZYME; LARGE ARTERIES; DRUG DOSE;
D O I
10.1097/00004872-199207005-00003
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: In treating hypertension the optimal dose of angiotensin converting enzyme (ACE) inhibitor is derived from dose-response curves that relate the quantity of drug taken to the resulting fall in blood pressure; the blood pressure fall reflects a decrease in vascular resistance and hence, a degree of arteriolar vasodilation. However, ACE inhibition dilates not only the small arteries but also the larger calibre arteries, which increases compliance. Given the differences in structure and function of large and small arteries, the optimal drug dose for a given vessel may differ according to the size and structure of the vessel. Dose-response effects in clinical studies: Clinical studies indicate that in the brachial artery territory, larger doses are required to obtain arterial dilation than to produce a decrease in vascular resistance. In the aorta, an improvement in arterial compliance and distensibility is governed both by the fall in blood pressure and the drug dose. Finally, for the femoral artery, the degree of arterial dilation is influenced markedly only by the drug dose. Application to treatment: An understanding of the drug dose required to produce a given change in the hypertensive arterial system may have important implications for the control of blood pressure. For a given mean arterial pressure, systolic blood pressure is lower and diastolic blood pressure higher when aortic compliance is increased, a haemodynamic change commonly seen following ACE inhibition. Recent double-blind studies have shown that ACE inhibitors produced a more pronounced decrease in systolic than diastolic blood pressure. Conclusion: These findings indicate that the optimum doses required to improve the arterial wall in large arteries must be evaluated by long-term antihypertensive therapy.
引用
收藏
页码:S13 / S19
页数:7
相关论文
共 36 条
  • [1] [Anonymous], 1984, Br J Clin Pharmacol, V18, P51
  • [2] ASMAR RG, 1988, J HYPERTENS, V6, pS79
  • [3] REVERSION OF CARDIAC-HYPERTROPHY AND REDUCED ARTERIAL COMPLIANCE AFTER CONVERTING ENZYME-INHIBITION IN ESSENTIAL-HYPERTENSION
    ASMAR, RG
    PANNIER, B
    SANTONI, JP
    LAURENT, S
    LONDON, GM
    LEVY, BI
    SAFAR, ME
    [J]. CIRCULATION, 1988, 78 (04) : 941 - 950
  • [4] ASMAR RG, 1992, IN PRESS J HYPERT S4, V10
  • [5] EFFECTS OF AGING ON CHANGING ARTERIAL COMPLIANCE AND LEFT-VENTRICULAR LOAD IN A NORTHERN CHINESE URBAN-COMMUNITY
    AVOLIO, AP
    CHEN, SG
    WANG, RP
    ZHANG, CL
    LI, MF
    OROURKE, MF
    [J]. CIRCULATION, 1983, 68 (01) : 50 - 58
  • [6] BENETOS A, 1991, J HUM HYPERTENS, V5, P363
  • [7] VASCULAR EFFECTS OF INTRAVENOUS-INFUSION OF THE ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR PERINDOPRILAT
    BENETOS, A
    SANTONI, JP
    SAFAR, ME
    [J]. JOURNAL OF HYPERTENSION, 1990, 8 (09) : 819 - 826
  • [8] HEMODYNAMIC-EFFECTS OF VASODILATING DRUGS ON THE COMMON CAROTID AND BRACHIAL CIRCULATIONS OF PATIENTS WITH ESSENTIAL-HYPERTENSION
    BOUTHIER, JD
    SAFAR, ME
    BENETOS, A
    SIMON, AC
    LEVENSON, JA
    HUGUES, CM
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (02) : 137 - 142
  • [9] BRUNNER HR, 1973, LANCET, V2, P1045
  • [10] HEMODYNAMICS OF ORALLY-ACTIVE CONVERTING ENZYME-INHIBITOR (SQ 14225) IN HYPERTENSIVE PATIENTS
    CODY, RJ
    TARAZI, RC
    BRAVO, EL
    FOUAD, FM
    [J]. CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1978, 55 (05): : 453 - 459